HU Alumnus to Give Special Lecture on His Research!

Sponsored by the HU Biotechnology Club! A special presentation to HU students:
CNChristian Njatcha, HU Alumni,
Pre-doctoral candidate, Cancer Research Grant
University of Minnesota.
“Targeting the EGFR/STAT3 pathway for the treatment of NSCLC”
Abstract: Lung cancer remains the most common cause of death from cancer in the US and there is a high need for improved therapeutic interventions. Non-Small Cell Lung Cancer (NSCLC) which accounts for 85% of all lung cancer cases, is often incurable and patients have a 5 year survival rate of only 16.8%. Epidermal growth factor receptor (EGFR) is a major target for the treatment of (NSCLC), but only a subset of patients with EGFR mutations benefit from EGFR tyrosine kinase inhibitors (TKIs) such as erlotinib (an FDA-approved drug). Intrinsic lack of response to erlotinib in wild-type (WT) EGFR and development of acquired resistance in mutant EGFR NSCLC are driven by mechanisms not fully understood. Signal transducer and activator of transcription 3 (Stat3) is a key mediator of EGFR signaling and other receptor tyrosine kinases (RTKs) such as the hepatocyte growth factor receptor (c-Met), fibroblast growth factor receptor (FGFR), and interleukin-6 (IL-6) receptor. STAT3 is constitutively activated in 65% of NSCLC. To address the problem of intrinsic and acquired resistance in NSCLC, we are using a novel approach to target STAT3 alone or in combination with TKIs.
Venue: HU Auditorium, 326 Market St, Harrisburg PA 17101.
Date: March 24th 2016;
Time: 10:30- 12 noon.